Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
All right, let's kick off the next session. Good afternoon, everyone. It is my pleasure to be hosting Olema Oncology and Sean Bowen, CEO of the company.
Sean, welcome.
Glad to be hosting you for another year at the GS Conference. Before, we have a lot to talk about. There's a lot going on, a lot of stuff coming out later on this year as well. Before we go there, I'm going to turn it to you for opening remarks.
Great.
Thank you, Rich. Well, thanks everyone for your interest.
Just reminding you, Alima is a company focused on.
Changing the treatment paradigm for positive HER2 negative breast cancer. This is the most common malignancy in women. It's the second most common cause of cancer death, and positive HER2 negative, 70% of it.
And we have two clinical stage assets.
The first is palisestrant, which is in two phase three programs ongoing. Our first readout, as we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
